ABL Bio Announces Clinical Collaboration to Evaluate ABL103 in Combination with KEYTRUDA® in Patients with Solid Tumors

ABL Bio, Inc. Denmark Finland Germany Netherlands Sweden United Kingdom South Korea New Jersey

View original content:https://www.prnewswire.co.uk/news-releases/abl-bio-announces-clinical-collaboration-to-evaluate-abl103-in-combination-with-keytruda-pembrolizumab-in-patients-with-solid-tumors-302267539.html